Prelamin A, Zmpste24, misshapen cell nuclei, and progeria - New evidence suggesting that protein farnesylation could be important for disease pathogenesis

Journal of Lipid Research

Volumn 46, Issue 12, 2005, Pages 2531-2558

  Young, Stephen G ^a   Fong, Loren G ^a   Michaelis, Susan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

a factor; Aging; Lamin A C; Laminopathy; Protein prenylation; Ste24

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; LAMIN A; LAMIN B; LAMIN B1; LAMIN B2; LAMIN C; PHEROMONE DERIVATIVE; PRELAMIN A; PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN ZMPSTE24; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BIOGENESIS; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL NUCLEUS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG HALF LIFE; DUNNIGAN TYPE FAMILIAL PARTIAL DYSTROPHY; DYSTROPHY; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENETIC DISORDER; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MANDIBULOACRAL DYSPLASIA; METHYLATION; MISSENSE MUTATION; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGERIA; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROCESSING; REVIEW; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS; YEAST;

ANIMALS; CELL NUCLEUS; FARNESYLTRANSTRANSFERASE; HUMANS; LIPOPROTEINS; NUCLEAR PROTEINS; PROGERIA; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES;

EID: 30844434561     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R500011-JLR200     Document Type: Review

References (153)

1. Zhang, F. L., and P. J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65: 241-269.
2. Clarke, S. 1992. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem. 61: 355-386.
3. Reiss, Y., M. S. Brown, and J. L. Goldstein. 1992. Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme. J. Biol. Chem. 267: 6403-6408.
4. Seabra, M. C., Y. Reiss, P. J. Casey, M. S. Brown, and J. L. Goldstein. 1991. Protein farnesyltransferase and geranylgeranyltransferase share a common α subunit. Cell. 65: 429-434.
5. Pereira-Leal, J. B., and M. C. Seabra. 2000. The mammalian Rab family of small GTPases: definition of family and subfamily sequence motifs suggests a mechanism for functional specificity in the Ras superfamily. J. Mol. Biol. 301: 1077-1087.
6. Seabra, M. C., and G. L. James. 1998. Prenylation assays for small GTPases. Methods Mol. Biol. 84: 251-260.
7. Seabra, M. C., E. H. Mules, and A. N. Hume. 2002. Rab GTPases, intracellular traffic and disease. Trends Mol. Med. 8: 23-30.
8. Brown, M. S., and J. L. Goldstein. 1993. Protein prenylation. Mad bet for Rab. Nature. 366: 14-15.
9. Young, S. G., P. Ambroziak, E. Kim, and S. Clarke. 2000. Postisoprenylation protein processing: CXXX (CaaX) endoproteases and isoprenylcysteine carboxyl methyltransferase. In The Enzymes. F. Tamanoi and D. S. Sigman, editors. Academic Press, San Diego, CA. 155-213.
10. Hrycyna, C. A., and S. Clarke. 1993. Modification of eukaryotic signaling proteins by C-terminal methylation reactions. Pharmacol. Ther. 59: 281-300.
11. Lin, F., and H. J. Worman. 1993. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J. Biol. Chem. 268: 16321-16326.
12. Mounkes, L. C., B. Burke, and C. L. Stewart. 2001. The A-type lamins. Nuclear structural proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends Cardiovasc. Med. 11: 280-285.
13. Burke, B., and C. L. Stewart. 2002. Life at the edge: the nuclear envelope and human disease. Nat. Rev. Mol. Cell Biol. 3: 575-585.
14. Hutchison, C. J., and H. J. Worman. 2004. A-type lamins: guardians of the soma? Nat. Cell Biol. 6: 1062-1067.
15. Eriksson, M., W. T. Brown, L. B. Gordon, M. W. Glynn, J. Singer, L. Scott, M. R. Erdos, C. M. Robbins, T. Y. Moses, P. Berglund, et al. 2003. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 423: 293-298.
16. Fong, L. G., J. K. Ng, M. Meta, N. Cote, S. H. Yang, C. L. Stewart, T. Sullivan, A. Burghardt, S. Majumdar, K. Reue, et al. 2004. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc. Natl. Acad. Sci. USA. 101: 18111-18116.
17. Chen, P., S. K. Sapperstein, J. D. Choi, and S. Michaelis. 1997. Biogenesis of the Saccharomyces cerevisiae mating pheromone a-factor. J. Cell Biol. 136: 251-269.
18. 2-terminal processing of the yeast a-factor precursor. J. Cell Biol. 136: 271-285.
19. Boyartchuk, V. L., and J. Rine. 1998. Roles of prenyl protein proteases in maturation of Saccharomyces cerevisiae a-factor. Genetics. 150: 95-101.
20. Boyartchuk, V. L., M. N. Ashby, and J. Rine. 1997. Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science. 275: 1796-1800.
21. Hrycyna, C. A., S. K. Sapperstein, S. Clarke, and S. Michaelis. 1991. The Saccharomyces cerevisiae STE14 gene encodes a methyltransferase that mediates C-terminal methylation of a-factor and Ras proteins. EMBO J. 10: 1699-1709.
22. Hrycyna, C. A., and S. Clarke. 1990. Farnesyl cysteine C-terminal methyltransferase activity is dependent upon the STE14 gene product in Saccharomyces cerevisiae. Mol. Cell. Biol. 10: 5071-5076.
23. Powers, S., S. Michaelis, D. Broek, S. Santa Anna., J. Field, I. Herskowitz, and M. Wigler. 1986. RAM, a gene of yeast required for a functional modification of RAS proteins and for production of mating pheromone a-factor. Cell. 47: 413-422.
24. He, B., P. Chen, S-Y. Chen, K. L. Vancura, S. Michaelis, and S. Powers. 1991. RAM2, an essential gene of yeast, and RAM1 encode the two polypeptide components of the farnesyltransferase that prenylates a-factor and Ras proteins. Proc. Natl. Acad. Sci. USA. 88: 11373-11377.
25. Casey, P. J. 1992. Biochemistry of protein prenylation. J. Lipid Res. 33: 1731-1740.
26. Casey, P. J., and M. C. Seabra. 1996. Protein prenyltransferases. J. Biol. Chem. 271: 5289-5292.
27. Schafer, W. R., and J. Rine. 1992. Protein prenylation: genes, enzymes, targets, and functions. Annu. Rev. Genet. 30: 209-237.
28. Clarke, S., J. P. Vogel, R. J. Deschenes, and J. Stock. 1988. Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases. Proc. Natl. Acad. Sci. USA. 85: 4643-4647.
29. Dai, Q., E. Choy, V. Chiu, J. Romano, S. R. Slivka, S. A. Steitz, S. Michaelis, and M. R. Philips. 1998. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J. Biol. Chem. 273: 15030-15034.
30. Hancock, J. F., A. I. Magee, J. E. Childs, and C. J. Marshall. 1989. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 57: 1167-1177.
31. Caldwell, G. A., F. Naider, and J. M. Becker. 1995. Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Microbiol. Rev. 59: 406-422.
32. Sapperstein, S., C. Berkower, and S. Michaelis. 1994. Nucleotide sequence of the yeast STE14 gene, which encodes farnesylcysteine carboxyl methyltransferase, and demonstration of its essential role in a-factor export. Mol. Cell. Biol. 14: 1438-1449.
33. Bergo, M. O., G. K. Leung, P. Ambroziak, J. C. Otto, P. J. Casey, and S. G. Young. 2000. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J. Biol. Chem. 275: 17605-17610.
34. Bergo, M. O., B. J. Gavino, C. Hong, A. P. Beigneux, M. McMahon, P. J. Casey, and S. G. Young. 2004. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J. Clin. Invest. 113: 539-550.
35. Kim, E., P. Ambroziak, J. C. Otto, B. Taylor, M. Ashby, K. Shannon, P. J. Casey, and S. G. Young. 1999. Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J. Biol. Chem. 274: 8383-8390.
36. Michaelson, D., W. Ali, V. K. Chiu, M. Bergo, J. Silletti, L. Wright, S. G. Young, and M. Philips. 2005. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol. Biol. Cell. 16: 1606-1616.
37. Sakagami, Y., M. Yoshida, A. Isogai, and A. Suzuki. 1981. Peptidal sex hormones inducing conjugation tube formation in compatible mating-type cells of Tremella mesenterica. Science. 212: 1525-1527.
38. Sakagami, Y., A. Isogai, A. Suzuki, S. Tamura, C. Kitada, and M. Fujino. 1979. Structure of tremerogen A-10, a peptidal hormone inducing conjugation tube formation in Tremella mesenterica. Agric. Biol. Chem. 43: 2643-2645.
39. Kamiya, A., A. Sakurai, S. Tamura, N. Takahashi, E. Tsuchiya, K. Abe, and S. Fukui. 1979. Structure of rhodotorucine A, a peptidyl factor, inducing mating tube formation in Rhodosporidium toruloides. Agric. Biol. Chem. 43: 363-369.
40. Ishibashi, Y., Y. Sakagami, A. Isogai, and A. Suzuki. 1984. Structures of tremerogens A-9291-I and A-9291-VIII: peptidyl sex hormones of Tremella brasiliensis. Biochemistry. 23: 1399-1404.
41. Ishibashi, Y., Y. Sakagami, A. Isogai, A. Suzuki, and R. J. Bandoni. 1983. Isolation of tremerogens A-9291-I and A-9291-II, novel sex hormones of Tremella brasiliensis. Can. J. Biochem. Cell Biol. 61: 796-801.
42. Sprague, G. F., and J. W. Thorner. 1992. Pheromone response and signal transduction during the mating process of Saccharomyces cerevisiae. In The Molecular and Cellular Biology of the Yeast Saccharomyces. E. W. Jones, J. R. Pringle, and J. R. Broach, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 657-744.
43. Anderegg, R. J., R. Betz, S. A. Carr, J. W. Crabb, and W. Duntze. 1988. Structure of Saccharomyces cerevisiae mating hormone a-factor. Identification of S-farnesyl cysteine as a structural component. J. Biol. Chem. 263: 18236-18240.
44. Michaelis, S., and S. Powers. 1988. Biogenesis of yeast mating pheromone a-factor and RAS proteins. In Molecular Biology of Intracellular Protein Sorting and Organelle Assembly. Alan R. Liss, New York. 193-202.
45. Michaelis, S. 1993. STE6, the yeast a-factor transporter. Semin. Cell Biol. 4: 17-27.
46. Schmidt, W. K., A. Tam, K. Fujimura-Kamada, and S. Michaelis. 1998. Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. Proc. Natl. Acad. Sci. USA. 95: 11175-11180.
47. 2-terminal proteolysis and COOH-terminal CAAX processing. J. Cell Biol. 142: 635-649.
48. Schmidt, W. K., A. Tam, and S. Michaelis. 2000. Reconstitution of the Ste24p-dependent N-terminal proteolytic step in yeast a-factor biogenesis. J. Biol. Chem. 275: 6227-6233.
49. 2-terminal processing of the yeast a-factor precursor. J. Biol. Chem. 276: 46798-46806.
50. Fujiyama, A., S. Tsunasawa, F. Tamanoi, and F. Sakiyama. 1991. S-Farnesylation and methyl esterification of C-terminal domain of yeast RAS2 protein prior to fatty acid acylation. J. Biol. Chem. 266: 17926-17931.
51. Hrycyna, C. A., S. J. Wait, P. S. Backlund, Jr., and S. Michaelis. 1995. Yeast STE14 methyltransferase, expressed as TrpE-STE14 fusion protein in Escherichia coli, for in vitro carboxylmethylation of prenylated polypeptides. Methods Enzymol. 250: 251-266.
52. Anderson, J. L., H. Frase, S. Michaelis, and C. A. Hrycyna. 2005. Purification, functional reconstitution, and characterization of the Saccharomyces cerevisiae isoprenylcysteine carboxylmethyltransferase Ste14p. J. Biol. Chem. 280: 7336-7345.
53. Schmidt, W. K., and S. Michaelis. 2004. Ste24 Protease. In Handbook of proteolytic enzymes (2nd edition). A. Barret, N. Rawlings and J. F. Woessner, editors. Academic Press, London. 460-465.
54. Leung, G. K., W. K. Schmidt, M. O. Bergo, B. Gavino, D. H. Wong, A. Tam, M. N. Ashby, S. Michaelis, and S. G. Young. 2001. Biochemical studies of Zmpste24-deficient mice. J. Biol. Chem. 276: 29051-29058.
55. Trueblood, C. E., V. L. Boyartchuk, E. A. Picologlou, D. Rozema, C. D. Poulter, and J. Rine. 2000. The CaaX proteases, Afc1p and Rce1p, have overlapping but distinct substrate specificities. Mol. Cell. Biol. 20: 4381-4392.
56. Michaelis, S., and I. Herskowitz. 1988. The a-factor pheromone of Saccharomyces cerevisiae is essential for mating. Mol. Cell. Biol. 8: 1309-1318.
57. Adames, N., K. Blundell, M. N. Ashby, and C. Boone. 1995. Role of yeast insulin-degrading enzyme homologs in propheromone processing and bud site selection. Science. 270: 464-467.
58. Otto, J. C., E. Kim, S. G. Young, and P. J. Casey. 1999. Cloning and characterization of a mammalian prenyl protein-specific protease. J. Biol. Chem. 274: 8379-8382.
59. Agarwal, A. K., J-P. Fryns, R. J. Auchus, and A. Garg. 2003. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum. Mol. Genet. 12: 1995-2001.
60. Kumagai, H., Y. Kawamura, K. Yanagisawa, and H. Komano. 1999. Identification of a human cDNA encoding a novel protein structurally related to the yeast membrane-associated metalloprotease, Ste24p. Biochim. Biophys. Acta. 1426: 468-474.
61. Freije, J. M. P., P. Blay, A. M. Pendás, J. Cadiñanos, P. Crespo, and C. López-Otín. 1999. Identification and chromosomal location of two human genes encoding enzymes potentially involved in proteolytic maturation of farnesylated proteins. Genomics. 58: 270-280.
62. Bergo, M. O., G. K. Leung, P. Ambroziak, J. C. Otto, P. J. Casey, A. Q. Gomes, M. C. Seabra, and S. G. Young. 2001. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J. Biol. Chem. 276: 5841-5845.
63. Maske, C. P., M. S. Hollinshead, N. C. Higbee, M. O. Bergo, S. G. Young, and D. J. Vaux. 2003. A carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease Rce1 and carboxymethylation. J. Cell Biol. 162: 1223-1232.
64. Bergo, M. O., P. Ambroziak, C. Gregory, A. George, J. C. Otto, E. Kim, H. Nagase, P. J. Casey, A. Balmain, and S. G. Young. 2002. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol. Cell. Biol. 22: 171-181.
65. Lin, X., J. Jung, D. Kang, B. Xu, K. S. Zaret, and H. Zoghbi. 2002. Prenylcysteine carboxylmethyltransferase is essential for the earliest stages of liver development in mice. Gastroenterology. 123: 345-351.
66. Smeland, T. E., M. C. Seabra, J. L. Goldstein, and M. S. Brown. 1994. Geranylgeranylated Rab proteins terminating in Cys-Ala-Cys, but not Cys-Cys, are carboxyl-methylated by bovine brain membranes in vitro. Proc. Natl. Acad. Sci. USA. 91: 10712-10716.
67. Silvius, J. R., and F. l'Heureux. 1994. Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers. Biochemistry. 33: 3014-3022.
68. Anderson, J. L., B. S. Henriksen, R. A. Gibbs, and C. A. Hrycyna. 2005. The isoprenoid substrate specificity of isoprenylcysteine carboxylmethyltransferase: development of novel inhibitors. J. Biol. Chem. 280: 29454-29461.
69. Winter-Vann, A. M., and P. J. Casey. 2005. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer. 5: 405-412.
70. Winter-Vann, A. M., R. A. Baron, W. Wong, J. dela Cruz, J. D. York, D. M. Gooden, M. O. Bergo, S. G. Young, E. J. Toone, and P. J. Casey. 2005. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl. Acad. Sci. USA. 102: 4336-4341.
71. Kohl, N. E., F. R. Wilson, S. D. Mosser, E. Giuliani, S. J. DeSolms, M. W. Conner, N. J. Anthony, W. J. Holtz, R. P. Gomez, T-J. Lee, et al. 1994. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA. 91: 9141-9145.
72. Gibbs, J. B., A. Oliff, and N. E. Kohl. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 77: 175-178.
73. Tamanoi, F. 1993. Inhibitors of Ras farnesyltransferases. Trends Biochem. Sci. 18: 349-353.
74. James, G. L., J. L. Goldstein, M. S. Brown, T. E. Rawson, T. C. Somers, R. S. McDowell, C. W. Crowley, B. K. Lucas, A. D. Levinson, and J. C. Marsters, Jr. 1993. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 260: 1937-1942.
75. Schmidt, R. A., C. J. Schneider, and J. A. Glomset. 1984. Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J. Biol. Chem. 259: 10175-10180.
76. Glomset, J. A., and C. C. Farnsworth. 1994. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu. Rev. Cell Biol. 10: 181-205.
77. Kim, C. M., J. L. Goldstein, and M. S. Brown. 1992. cDNA cloning of MEV, a mutant protein that facilitates cellular uptake of mevalonate, and identification of the point mutation responsible for its gain of function. J. Biol. Chem. 267: 23113-23121.
78. Wilson, K. L. 2000. The nuclear envelope, muscular dystrophy and gene expression. Trends Cell Biol. 10: 125-129.
79. Bergo, M. O., B. Gavino, J. Ross, W. K. Schmidt, C. Hong, L. V. Kendall, A. Mohr, M. Meta, H. Genant, Y. Jiang, et al. 2002. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. USA. 99: 13049-13054.
80. Bergo, M. O., and S. G. Young. 2005. Zmpste24 (mammalian farnesylated protein-converting enzyme 1). In Handbook of Proteolytic Enzymes. A. J. Barrett, N. D. Rawlings, and J. F. Woessner, editors. Academic Press, London. In press.
81. Corrigan, D. P., D. Kuszczak, A. E. Rusinol, D. P. Thewke, C. A. Hrycyna, S. Michaelis, and M. S. Sinensky. 2005. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem. J. 387: 129-138.
82. Kilic, F., M. B. Dalton, S. K. Burrell, J. P. Mayer, S. D. Patterson, and M. Sinensky. 1997. In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease. J. Biol. Chem. 272: 5298-5304.
83. Pendás, A. M., Z. Zhou, J. Cadiñanos, J. M. P. Freije, J. Wang, K. Hultenby, A. Astudillo, A. Wernerson, F. Rodríguez, K. Tryggvason, et al. 2002. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat. Genet. 31: 94-99.
84. Fisher, D. Z., N. Chaudhary, and G. Blobel. 1986. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc. Natl. Acad. Sci. USA. 83: 6450-6454.
85. Chelsky, D., C. Sobotka, and C. L. O'Neill. 1989. Lamin B methylation and assembly into the nuclear envelope. J. Biol. Chem. 264: 7637-7643.
86. Izumi, M., O. A. Vaughan, C. J. Hutchison, and D. M. Gilbert. 2000. Head and/or CaaX domain deletions of lamin proteins disrupt preformed lamin A and C but not lamin B structure in mammalian cells. Mol. Biol. Cell. 11: 4323-4337.
87. Beck, L. A., T. J. Hosick, and M. Sinensky. 1990. Isoprenylation is required for the processing of the lamin A precursor. J. Cell Biol. 110: 1489-1499.
88. Hennekes, H., and E. A. Nigg. 1994. The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J. Cell Sci. 107: 1019-1029.
89. Vaughan, O. A., M. Alvarez-Reyes, J. M. Bridger, J. L. V. Broers, F. C. S. Ramaekers, M. Wehnert, G. E. Morris, W. G. F. Whitfield, and C. J. Hutchison. 2001. Both emerin and lamin C depend on lamin A for localization at the nuclear envelope. J. Cell Sci. 114: 2577-2590.
90. Dalton, M., and M. Sinensky. 1995. Expression systems for nuclear lamin proteins: farnesylation in assembly of nuclear lamina. Methods Enzymol. 250: 134-148.
91. Kilic, F., D. A. Johnson, and M. Sinensky. 1999. Subcellular localization and partial purification of prelamin A endoprotease: an enzyme which catalyzes the conversion of farnesylated prelamin A to mature lamin A. FEBS Lett. 450: 61-65.
92. Hegele, R. A. 2000. Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome. Mol. Genet. Metab. 71: 539-544.
93. Hegele, R. A. 2001. Molecular basis of partial lipodystrophy and prospects for therapy. Trends Mol. Med. 7: 121-126.
94. Garg, A. 2000. Lipodystrophies. Am. J. Med. 108: 143-152.
95. Bonne, G., M. R. Di Barletta, S. Varnous, H-M. Bécane, E-H. Hammouda, L. Merlini, F. Muntoni, C. R. Greenberg, F. Gary, J-A. Urtizberea, et al. 1999. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat. Genet. 21: 285-288.
96. Vytopil, M., S. Benedetti, E. Ricci, G. Galluzzi, A. D. Russo, L. Merlini, G. Boriani, M. Gallina, L. Morandi, L. Politano, et al. 2003. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J. Med. Genet. 40: 132.
97. De Sandre-Giovannoli, A., M. Chaouch, S. Kozlov, J-M. Vallat, M. Tazir, N. Kassouri, P. Szepetowski, T. Hammadouche, A. Vandenberghe, C. L. Stewart, et al. 2002. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am. J. Hum. Genet. 70: 726-736.
98. Novelli, G., A. Muchir, F. Sangiuolo, A. Helbling-Leclerc, M. R. D'Apice, C. Massart, F. Capon, P. Sbraccia, M. Federici, R. Lauro, et al. 2002. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am. J. Hum. Genet. 71: 426-431.
99. Chen, L., L. Lee, B. A. Kudlow, H. G. Dos Santos, O. Sletvold, Y. Shafeghati, E. G. Botha, A. Garg, N. B. Hanson, G. M. Martin, et al. 2003. LMNA mutations in atypical Werner's syndrome. Lancet. 362: 440-445.
100. Hegele, R. A. 2003. Drawing the line in progeria syndromes. Lancet. 362: 416-417.
101. Dhe-Paganon, S., E. D. Werner, Y-I. Chi, and S. E. Shoelson. 2002. Structure of the globular tail of nuclear lamin. J. Biol. Chem. 277: 17381-17384.
102. Krimm, I., C. Ostlund, B. Gilquin, J. Couprie, P. Hossenlopp, J. P. Mornon, G. Bonne, J. C. Courvalin, H. J. Worman, and S. Zinn-Justin. 2002. The Ig-like structure of the C-terminal domain of lamin A/C, mutated in muscular dystrophies, cardiomyopathy, and partial lipodystrophy. Structure (Camb). 10: 811-823.
103. Garg, A., O. Cogulu, F. Ozkinay, H. Onay, and A. K. Agarwal. 2005. A novel homozygous Ala529Val LMNA mutation in Turkish patients with mandibuloacral dysplasia. J. Clin. Endocrinol. Metab. 90: 5259-5264.
104. Muchir, A., J. Medioni, M. Laluc, C. Massart, T. Arimura, A. J. van der Kooi, I. Desguerre, M. Mayer, X. Ferrer, S. Briault, et al. 2004. Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations. Muscle Nerve. 30: 444-450.
105. Wilson, K. L., M. S. Zastrow, and K. K. Lee. 2001. Lamins and disease: insights into nuclear infrastructure. Cell. 104: 647-650.
106. Hutchison, C. J., M. Alvarez-Reyes, and O. A. Vaughan. 2001. Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes? J. Cell Sci. 114: 9-19.
107. Lammerding, J., P. C. Schulze, T. Takahashi, S. Kozlov, T. Sullivan, R. D. Kamm, C. L. Stewart, and R. T. Lee. 2004. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J. Clin. Invest. 113: 370-378.
108. -/- cells is caused by defective nucleo-cytoskeletal integrity: implications for the development of laminopathies. Hum. Mol. Genet. 13: 2567-2580.
109. Vergnes, L., M. Peterfy, M. O. Bergo, S. G. Young, and K. Reue. 2004. Lamin B1 is required for mouse development and nuclear integrity. Proc. Natl. Acad. Sci. USA. 101: 10428-10433.
110. Sullivan, T., D. Escalante-Alcalde, H. Bhatt, M. Anver, N. Bhat, K. Nagashima, C. L. Stewart, and B. Burke. 1999. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J. Cell Biol. 147: 913-919.
111. Cutler, D. A., T. Sullivan, B. Marcus-Samuels, C. L. Stewart, and M. L. Reitman. 2002. Characterization of adiposity and metabolism in Lmna-deficient mice. Biochem. Biophys. Res. Commun. 291: 522-527.
112. Raharjo, W. H., P. Enarson, T. Sullivan, C. L. Stewart, and B. Burke. 2001. Nuclear envelope defects associated with LMNA mutations cause dilated cardiomyopathy and Emery-Dreifuss muscular dystrophy. J. Cell Sci. 114: 4447-4457.
113. Muchir, A., B. G. van Engelen, M. Lammens, J. M. Mislow, E. Mc-Nally, K. Schwartz, and G. Bonne. 2003. Nuclear envelope alterations in fibroblasts from LGMD1B patients carrying nonsense Y259X heterozygous or homozygous mutation in lamin A/C gene. Exp. Cell Res. 291: 352-362.
114. Weber, K., U. Plessmann, and P. Traub. 1989. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor: implications for the structure of the nuclear lamina. FEBS Lett. 257: 411-414.
115. Young, S. G., S. Clarke, M. Bergo, M. Philips, and L. G. Fong. 2005. Genetic approaches to understanding the physiologic importance of the carboxyl methylation of isoprenylated proteins. The Enzymes. In press.
116. Toth, J. I., S. H. Yang, X. Qiao, A. P. Beigneux, M. H. Gelb, C. L. Moulson, J. H. Miner, S. G. Young, and L. G. Fong. 2005. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc. Natl. Acad. Sci. USA. 102: 12873-12878.
117. Yang, S. H., M. O. Bergo, J. I. Toth, X. Qiao, Y. Hu, S. Sandoval, M. Meta, P. Bendale, M. H. Gelb, S. G. Young, et al. 2005. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts containing a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl. Acad. Sci. USA. 102: 10291-10296.
118. Cahill, G. F., Jr. 1970. Starvation in man. N. Engl. J. Med. 282: 668-675.
119. Mounkes, L. C., S. Kozlov, L. Hernandez, T. Sullivan, and C. L. Stewart. 2003. A progeroid syndrome in mice is caused by defects in A-type lamins. Nature. 423: 298-301.
120. Olson, E. N., H-H. Arnold, P. W. J. Rigby, and B. J. Wold. 1996. Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell. 85: 1-4.
121. Varela, I., J. Cadinanos, A. M. Pendas, A. Gutierrez-Fernandez, A. R. Folgueras, L. M. Sanchez, Z. Zhou, F. J. Rodriguez, C. L. Stewart, J. A. Vega, et al. 2005. Accelerated ageing in mice defi-cient in Zmpste24 protease is linked to p53 signalling activation. Nature. 437: 564-568.
122. Debusk, F. L., B. Burke, and C. L. Stewart. 1972. The Hutchinson-Gilford progeria syndrome. J. Pediatr. 80: 697-724.
123. Cao, H., and R. A. Hegele. 2003. LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J. Hum. Genet. 48: 271-274.
124. de Sandre-Giovannoli, A., R. Bernard, P. Cau, C. Navarro, J. Amiel, I. Boccaccio, S. Lyonnet, C. L. Stewart, A. Munnich, M. Le Merrer, et al. 2003. Lamin A truncation in Hutchinson-Gilford progeria. Science. 300: 2055.
125. Reddel, C. J., and A. S. Weiss. 2004. Lamin A expression levels are unperturbed at the normal and mutant alleles but display partial splice site selection in Hutchinson-Gilford progeria syndrome. J. Med. Genet. 41: 715-717.
126. Goldman, R. D., D. K. Shumaker, M. R. Erdos, M. Eriksson, A. E. Goldman, L. B. Gordon, Y. Gruenbaum, S. Khuon, M. Mendez, R. Varga, et al. 2004. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA. 101: 8963-8968.
127. Capell, B. C., M. R. Erdos, J. P. Madigan, J. J. Fiordalisi, R. Varga, K. N. Conneely, L. B. Gordon, C. J. Der, A. D. Cox, and F. S. Collins. 2005. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA. 102: 12879-12884.
128. Corso, C., E. M. Parry, R. G. Faragher, A. Seager, M. H. Green, and J. M. Parry. 2005. Molecular cytogenetic insights into the ageing syndrome Hutchinson-Gilford progeria (HGPS). Cytogenet. Genome Res. 111: 27-33.
129. Csoka, A. B., H. Cao, P. J. Sammak, D. Constantinescu, G. P. Schatten, and R. A. Hegele. 2004. Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes. J. Med. Genet. 41: 304-308.
130. Capanni, C., E. Mattioli, M. Columbaro, E. Lucarelli, V. K. Parnaik, G. Novelli, M. Wehnert, V. Cenni, N. M. Maraldi, S. Squarzoni, et al. 2005. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum. Mol. Genet. 14: 1489-1502.
131. Navarro, C., A. D. Sandre-Giovannoli, R. Bernard, I. Bocccaccio, A. Boyer, D. Genevieve, S. Hadj-Raabia, C. Gaudy-Marqueste, H. S. Smitt, P. Vabres, et al. 2004. Lamin A and ZMPSTE24 defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum. Mol. Gen. 13: 2493-2503.
132. Moulson, C. L., G. Go, J. M. Gardner, A. C. van der Wal, J. H. S. Smitt, J. M. van Hagen, and J. H. Miner. 2005. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest. Dermatol. In press.
133. Navarro, C. L., J. Cadinanos, A. De Sandre-Giovannoli, R. Bernard, S. Courrier, I. Boccaccio, A. Boyer, W. J. Kleijer, A. Wagner, F. Giuliano, et al. 2005. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of lamin A precursors. Hum. Mol. Genet. 14: 1503-1513.
134. Mounkes, L. C., S. V. Kozlov, J. N. Rottman, and C. L. Stewart. 2005. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum. Mol. Genet. 14: 2167-2180.
135. Arimura, T., A. Helbling-Leclerc, C. Massart, S. Varnous, F. Niel, E. Lacene, Y. Fromes, M. Toussaint, A. M. Mura, D. I. Keller, et al. 2005. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum. Mol. Genet. 14: 155-169.
136. Shackleton, S., D. T. Smallwood, P. Clayton, L. C. Wilson, A. K. Agarwal, A. Garg, and R. C. Trembath. 2005. Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing and result in a severe progeroid phenotype. J. Med. Genet. 42: e36.
137. Mallampalli, M. P., G. Huyer, P. Bendale, M. H. Gelb, and S. Michaelis. 2005. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA. 102: 14416-14421.
138. Rodenhuis, S. 1992. ras and human tumors. Semin. Cancer Biol. 3: 241-247.
139. Bos, J. L. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689.
140. Whyte, D. B., P. Kirschmeier, T. N. Hockenberry, I. Nunez-Oliva, L. James, J. J. Catino, W. R. Bishop, and J-K. Pai. 1997. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272: 14459-14464.
141. Glynn, M. W., and T. W. Glover. 2005. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum. Mol. Genet. 14: 2959-2969.
142. Alsina, M., R. Fonseca, E. F. Wilson, A. N. Belle, E. Gerbino, T. Price-Troska, R. M. Overton, G. Ahmann, L. M. Bruzek, A. A. Adjei, et al. 2004. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 103: 3271-3277.
143. Izbicka, E., D. Campos, G. Carrizales, and A. Patnaik. 2005. Biomarkers of anticancer activity of R115777 (tipifarnib, zarnestra) in human breast cancer models in vitro. Anticancer Res. 25: 3215-3223.
144. Adjei, A. A., J. N. Davis, C. Erlichman, P. A. Svingen, and S. H. Kaufmann. 2000. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. 6: 2318-2325.
145. Adjei, A. A., G. A. Croghan, C. Erlichman, R. S. Marks, J. M. Reid, J. A. Sloan, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, et al. 2003. A phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 9: 2520-2526.
146. Kim, E. S., M. S. Kies, F. V. Fossella, B. S. Glisson, S. Zaknoen, P. Statkevich, R. F. Munden, C. Summey, K. M. Pisters, V. Papadimitrakopoulou, et al. 2005. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 104: 561-569.
147. Ferguson, D., L. E. Rodriguez, J. P. Palma, M. Refici, K. Jarvis, J. O'Connor, G. M. Sullivan, D. Frost, K. Marsh, J. Bauch, et al. 2005. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin. Cancer Res. 11: 3045-3054.
148. Rao, S., D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y. Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, et al. 2004. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 22: 3950-3957.
149. Oades, G. M., S. G. Senaratne, I. A. Clarke, R. S. Kirby, and K. W. Colston. 2003. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J. Urol. 170: 246-252.
150. Rogers, M. J. 2003. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9: 2643-2658.
151. Scaffidi, P., and T. Misteli. 2005. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat. Med. 11: 440-445.
152. Csoka, A. B., S. B. English, C. P. Simkevich, D. G. Ginzinger, A. J. Butte, G. P. Schatten, F. G. Rothman, and J. M. Sedivy. 2004. Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread
153. Liu, B., J. Wang, K. M. Chan, W. M. Tjia, W. Deng, X. Guan, J. D. Huang, K. M. Li, P. Y. Chau, D. J. Chen, et al. 2005. Genomic instability in laminopathy-based premature aging. Nat. Med. 11: 780-785.